Estrogen Breakthrough: How Pregnancy Hormones Could Transform MS Treatment

Researchers have made an exciting discovery about estrogen's potential for treating progressive multiple sclerosis. The study found that both estradiol and estriol show promise in reducing MS symptoms using virus models of the disease. This research was inspired by the observation that pregnant women with MS often experience remission during pregnancy when estrogen levels are elevated. The findings could lead to new therapeutic interventions for the challenging progressive form of MS.

Key Points: Estrogen Shows Promise for Progressive Multiple Sclerosis Therapy

  • Estradiol significantly reduces damage to protective nerve coating myelin sheath
  • Both estrogen types decrease spinal cord inflammation in MS models
  • Study uses virus models mimicking progressive multiple sclerosis symptoms
  • Research builds on observation that pregnant MS patients experience remission
3 min read

Multidisciplinary study finds estrogen could aid in therapies for progressive multiple sclerosis

Texas A&M researchers discover estradiol and estriol reduce MS symptoms in virus models, offering new hope for progressive multiple sclerosis treatment.

"Testing potential therapies by using virus models of the disease is important because we recently learned that the Epstein-Barr virus contributes to the formation and development of MS - Jane Welsh"

Texas, October 14

About 100,000 of the estimated million persons in the United States with multiple sclerosis (MS) have a progressive form of the disease, with symptoms worsening over time or following periods of remission.

"Progressive MS is profoundly challenging because it is relentless and treatment options are limited," said Francisco P. Gomez, a neurologist who specializes in MS and neuroimmunology.

MS is believed to occur when the immune system attacks the myelin sheath -- the protective coating of the nerve fibers that transmit electrical impulses throughout the body -- and disrupt this communication. The disease occurs more often in women, older people and those in northern latitudes.

Symptoms include fatigue, numbness or tingling, bladder and bowel problems and cognitive issues, but difficulty walking and balancing are the most common symptoms -- and these are more pronounced in the progressive form of the disease. In addition, the progressive form is more prevalent among Black patients.

Now, Gomez and colleagues with the Texas A&M University Health Science Center (Texas A&M Health) have identified two estrogens that show promise in reducing the symptoms of progressive MS: estradiol and estriol.

For their study, published in the Journal of Neuroimmunology, the team evaluated estriol and estradiol as possible treatment protocols through a study that used a virus to mimic progressive MS.

"Testing potential therapies by using virus models of the disease is important because we recently learned that the Epstein-Barr virus contributes to the formation and development of MS by triggering an autoimmune response in susceptible individuals," said study author Jane Welsh, a neuroimmunologist with the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) and the Texas A&M Naresh K. Vashist College of Medicine.

She added that while women are more likely than men to develop MS, once they have the disease and become pregnant, they tend to go into remission.

"That's because during pregnancy -- and especially in the third trimester -- estradiol and estriol levels are elevated," said study author Candice Brinkmeyer-Langford, a neurogenerative disease expert with the Texas A&M School of Public Health. "Even women with MS who are on oral contraceptives experience fewer symptoms and have fewer relapses, so we evaluated how these hormones affect the myelin sheath."

Estrogen is a group of hormones that primarily affect sex drive and reproductive development, especially for women.

Estradiol is more potent than estriol and is used for hormone replacement therapy in postmenopausal women. Estriol, on the other hand, is used off-label for a variety of conditions and is FDA-approved only for treating urinary incontinence in dogs.

The researchers found that both types of estrogen decreased inflammation in the spinal cord, but only estradiol significantly decreased the damage to the myelin sheath, and believe this could aid in the development of therapeutic interventions for people with progressive MS.

- ANI

Share this article:

Reader Comments

R
Rohit P
Interesting study but I'm concerned about potential side effects of estrogen therapy. Hormone treatments can be tricky - we need more research before jumping to conclusions. Still, any progress against MS is welcome news.
D
David E
The Epstein-Barr virus connection is crucial! This could explain why MS prevalence varies globally. In India, we see different patterns than Western countries - maybe viral exposure differences play a role?
A
Ananya R
As a medical student in Mumbai, this research is exciting! The fact that estradiol showed better results for myelin protection is significant. Hope Indian research institutions collaborate on similar studies for our population.
S
Sarah B
The mention that progressive MS is more prevalent among Black patients is important - we need to ensure diverse clinical trials so treatments work for all ethnic groups. Representation matters in medical research! ✊
V
Vikram M
Good to see research focusing on progressive MS which is often neglected. My mother has been struggling with walking difficulties for years. Any new treatment approach gives us hope. When might this reach clinical trials in India?

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50